Cellular composition of fresh lymph node samples from mice transplanted with leukemic cells from Pax5+/−Ebf1+/− mice
| Donor lymph node . | Percentage of live cells* (CD45.2) . | Lymph nodes (percentage of CD45.2)* . | |||||
|---|---|---|---|---|---|---|---|
| NK1.1+ . | CD3+ . | CD19+B220+ . | CD43highIgM− . | CD43low/negIgM− . | CD43low/negIgM+ . | ||
| 277 (n = 4)† | 23.8 (16.1-31.4) | 0.0 | 0.1 (0.1-0.2) | 86.8 (85.8-91.5) | 85.5 (84.5-89.8) | 0.1 (0.1-0.2) | 0.0 |
| 278 (n = 7)† | 9.7 (6.7-19.5) | 0.1 (0.0-0.2) | 0.0 | 96.4 (93.9-97.5) | 83.0 (78.8-86.9) | 4.0 (2.5-6.3) | 0.0 |
| 327 (n = 4)† | 42.2 (32.2-62.6) | 0.0 | 0.5 (0.1-1.8) | 98.0 (97.9-98.2) | 97.2 (96.4-98.0) | 0.0 | 0.0 |
| 278 (n = 4)‡ | 39.5 (25.1-67.7) | 0.0 | 0.2 (0.1-0.2) | 98.2 (98.1-98.5) | 91.3 (90.0-92.9) | 2.1 (2.1-2.9) | 0.0 |
| 292 (n = 3)‡ | 55.8 (47.2-57.1) | 0.0 | 0.2 (0.0-0.3) | 99.2 (98.9-99.3) | 60.5 (56.7-65.3) | 31.7 (27.2-35.4) | 0.1 (0.0-0.1) |
| Donor lymph node . | Percentage of live cells* (CD45.2) . | Lymph nodes (percentage of CD45.2)* . | |||||
|---|---|---|---|---|---|---|---|
| NK1.1+ . | CD3+ . | CD19+B220+ . | CD43highIgM− . | CD43low/negIgM− . | CD43low/negIgM+ . | ||
| 277 (n = 4)† | 23.8 (16.1-31.4) | 0.0 | 0.1 (0.1-0.2) | 86.8 (85.8-91.5) | 85.5 (84.5-89.8) | 0.1 (0.1-0.2) | 0.0 |
| 278 (n = 7)† | 9.7 (6.7-19.5) | 0.1 (0.0-0.2) | 0.0 | 96.4 (93.9-97.5) | 83.0 (78.8-86.9) | 4.0 (2.5-6.3) | 0.0 |
| 327 (n = 4)† | 42.2 (32.2-62.6) | 0.0 | 0.5 (0.1-1.8) | 98.0 (97.9-98.2) | 97.2 (96.4-98.0) | 0.0 | 0.0 |
| 278 (n = 4)‡ | 39.5 (25.1-67.7) | 0.0 | 0.2 (0.1-0.2) | 98.2 (98.1-98.5) | 91.3 (90.0-92.9) | 2.1 (2.1-2.9) | 0.0 |
| 292 (n = 3)‡ | 55.8 (47.2-57.1) | 0.0 | 0.2 (0.0-0.3) | 99.2 (98.9-99.3) | 60.5 (56.7-65.3) | 31.7 (27.2-35.4) | 0.1 (0.0-0.1) |
Cellular composition of fresh lymph node samples from mice transplanted with leukemic cells from Pax5+/−Ebf1+/− mice 2 to 3 weeks after transplantation. The numbers in the far left column indicate the identity of the original mouse with developed malignancy. The FACS analysis was based on surface expression of CD45.2 to identify transplanted cells and the NK cell marker NK1.1, the T-lineage marker CD3, and the B-lineage markers CD19 and B220. The subcomposition of the CD19+B220+ population was further investigated based on the expression of CD43and IgM. The data in the first column indicate the frequency of live CD45.2+ cells in each of the samples, whereas the remaining columns indicate percentage of CD45.2+ cells.
Median ± interquartile range.
Sublethally irradiated (4.5 Gy) CD45.1 recipient mice.
Nonirradiated CD45.1 recipient mice.